Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zosano Pharma (ZSAN)

Zosano Pharma (ZSAN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,851
  • Shares Outstanding, K 17,723
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,360 K
  • 60-Month Beta 2.62
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +147,011.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.41 +35.46%
on 10/03/19
2.03 -5.91%
on 09/19/19
-0.12 (-5.91%)
since 09/16/19
3-Month
1.41 +35.46%
on 10/03/19
3.35 -42.99%
on 07/19/19
-1.34 (-41.23%)
since 07/16/19
52-Week
1.41 +35.46%
on 10/03/19
6.65 -71.28%
on 02/21/19
-2.11 (-52.49%)
since 10/16/18

Most Recent Stories

More News
Zosano Pharma Announces CEO Transition

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Steven Lo, veteran biotechnology and pharmaceutical executive, will become president and chief...

ZSAN : 1.91 (+13.02%)
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 100,000 shares of Zosano's common stock...

ZSAN : 1.91 (+13.02%)
Zosano Pharma to Present at the Cantor Global Healthcare Conference

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will present a company overview...

ZSAN : 1.91 (+13.02%)
Zosano Pharma Announces the Appointment of Dushyant Pathak, Ph.D., as Senior Vice President of Business Development

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Dushyant Pathak, Ph.D., as senior vice president of business development.

ZSAN : 1.91 (+13.02%)
Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta(TM) Long-Term Safety Study at the Congress of the International Headache Society

- Repeated Dosing of Qtrypta Over the Course of One Year Reaffirms Qtrypta is Effective and Well-Tolerated as an Acute Treatment for Migraine -

ZSAN : 1.91 (+13.02%)
Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will present a company overview...

ZSAN : 1.91 (+13.02%)
Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company will deliver an oral presentation and two poster presentations at the 19th Congress...

ZSAN : 1.91 (+13.02%)
Jaguar Health Appoints Carol Lizak Chief Accounting Officer

SAN FRANCISCO, CA / ACCESSWIRE / August 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived...

ALXA : 1.0000 (+6.95%)
ZSAN : 1.91 (+13.02%)
JAGX : 0.73 (+2.33%)
Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2019, as well as recent business highlights....

ZSAN : 1.91 (+13.02%)
Zosano Pharma Files IND to Initiate a Phase 2/3 Clinical Study in Cluster Headache

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug...

ZSAN : 1.91 (+13.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ZSAN with:

Business Summary

Zosano Pharma Corporation is a biopharmaceutical company. It is engaged in developing a transdermal micro needle patch system to deliver formulations of existing drugs through the skin for the treatment of a variety of indications. The Company's lead product candidates include Weekly ZP-PTH for severe...

See More

Key Turning Points

2nd Resistance Point 2.16
1st Resistance Point 2.03
Last Price 1.91
1st Support Level 1.74
2nd Support Level 1.58

See More

52-Week High 6.65
Fibonacci 61.8% 4.65
Fibonacci 50% 4.03
Fibonacci 38.2% 3.41
Last Price 1.91
52-Week Low 1.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar